Magazine Article | August 9, 2017

Alternatives To Funding Lower-Priority Trials

Source: Life Science Leader

By Suzanne Elvidge, Contributing Editor
Follow Me On Twitter @suzannewriter

While some pharma companies struggle to backfill their pipelines, others find the opposite, that they have more development opportunities than they can pursue. While this may seem to be a nice problem to have — the luxury to be able to choose the very best of the very best — it also means that otherwise good drug candidates may be pushed down the list of priorities.